论文部分内容阅读
目的:观察重组人血管内皮抑制素(恩度)联合TP方案治疗晚期非小细胞肺癌(NSCLC)的近期疗效和不良反应。方法:常规TP方案化疗,即紫杉醇150mg/m2,第1天;顺铂25mg/m2,第1～3天;同时联合恩度15mg/d,第1～14天。21d为1个周期,至少完成2个周期。结果:总有效率41.4%,不良反应较轻微,耐受好。结论:恩度联合TP方案化疗治疗晚期NSCLC近期疗效好,不良反应轻微,耐受性好,安全性高,值得临床推广应用。
Objective: To observe the short-term efficacy and adverse reactions of recombinant human endostatin (Endostar) combined with TP regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: The conventional TP regimen chemotherapy, namely paclitaxel 150mg / m2, the first day; cisplatin 25mg / m2, 1 to 3 days; at the same time enamel 15mg / d, 1 to 14 days. 21d for a period of at least 2 cycles completed. Results: The total effective rate was 41.4%, mild adverse reactions, well tolerated. Conclusion: Endo combined with TP regimen in the treatment of advanced NSCLC has good curative effect, mild side effects, good tolerance and high safety. It is worthy of clinical application.